Talk:Pablo Legorreta
Latest comment: 1 year ago by Tonyrexlibidine in topic Possible Future Citations to be Used
| This article must adhere to the biographies of living persons (BLP) policy, even if it is not a biography, because it contains material about living persons. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libellous. If such material is repeatedly inserted, or if you have other concerns, please report the issue to this noticeboard.If you are a subject of this article, or acting on behalf of one, and you need help, please see this help page. |
 | This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||
| ||||||||
Possible Future Citations to be Used
editThe Private Equity Firm That Quietly Profits on Top-Selling Drugs - The New York Times (nytimes.com) https://www.forbes.com/sites/nathanvardi/2020/06/12/meet-the-secretive-wall-street-investor-with-the-billion-dollar-medicine-cabinet/ Brothers Make Billions From Ex-Merger Banker’s Pharma Firm - Bloomberg Moderna goes on the patent offensive; Pablo Legorreta doubles down; Is a biotech recovery on the way?; and more – Endpoints News (endpts.com) Pablo Legorreta | The New York Academy of Sciences (nyas.org) Tonyrexlibidine (talk) 23:41, 29 July 2023 (UTC)